FIELD: biotechnology.
SUBSTANCE: invention relates to variants of factor H-binding proteins, and can be used in medicine to induce a humoral response against N. meningitidis in a mammal. The resulting protein is a variant factor of H-binding protein (fHbp) of A subfamily, which contains the amino acid substitution G220S and optional amino acid substitutions L130R and G133D; wherein the amino acid substitutions are substitutions in relation to fHbp ID 22, where the amino acid positions are numbered relative to the amino acid sequence of fHbp ID1.
EFFECT: invention provides an fHbp variant that binds human factor H (fH) with an affinity that is 50% or less of the fHbp ID 22 affinity for human fH, and the variant produces a bactericidal humoral response in a mammal.
21 cl, 40 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| VERSIONS OF FACTOR N-BINDING PROTEIN AND METHODS OF USE THEREOF | 2015 |
|
RU2714248C2 |
| MODIFIED PROTEIN BINDING FACTOR H | 2017 |
|
RU2773464C1 |
| NEISSERIA MENINGITIDIS COMPOSITIONS AND METHODS FOR USING THEM | 2017 |
|
RU2739504C2 |
| FUSED PROTEIN CONSTRUCTS FOR COMPLEMENT-RELATED DISEASE | 2019 |
|
RU2824402C2 |
| EMBODIMENTS OF IGG-Fc FOR USE IN VETERINARY SCIENCE | 2018 |
|
RU2814952C2 |
| NEW VERSIONS OF HYALURONIDASE WITH IMPROVED STABILITY AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM | 2021 |
|
RU2811464C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES AND METHODS OF THEIR USE | 2019 |
|
RU2800779C2 |
| STRUCTURES HAVING SIRP-ALPHA DOMAIN OR ITS VERSION | 2016 |
|
RU2740672C2 |
| COMPOSITION FOR CULTURING REGULATORY T-CELLS AND ITS APPLICATION | 2020 |
|
RU2807802C1 |
| COMPOSITIONS AND METHODS OF GENE EDITING | 2019 |
|
RU2804665C2 |
